Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.

Literature DB >> 27209246

Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.

Marieke Arts-de Jong¹, Geertruida H de Bock², Christi J van Asperen³, Marian J E Mourits⁴, Joanne A de Hullu⁵, C Marleen Kets⁶.

Abstract

The presence of a germline BRCA1/2 mutation improves options for tailored risk-reducing strategies and treatment in both breast and ovarian cancer patients and their relatives. Currently, referral for germline BRCA1/2 mutation testing of women with epithelial ovarian cancer (EOC) varies widely, based on different criteria, such as age of onset, family history of breast and/or ovarian cancer and histological type of EOC. The overall probability of a germline BRCA1/2 mutation in women with EOC is above 10%, and a substantial part of the germline BRCA1/2 mutation carriers is missed when applying these criteria for referral. Therefore, we strongly recommend referral of all women with EOC for genetic counselling and DNA analysis.

Entities: Disease Gene Species

Keywords: BRCA mutation; Epithelial ovarian cancer; Genetic testing; Probability; Referral

Mesh：

Substances：

Year: 2016 PMID： 27209246 DOI： 10.1016/j.ejca.2016.03.009

Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162

Keyword Cloud
Cited

18 in total

Review 1. Ovarian Cancer Prevention in High-risk Women.

Authors: Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal: Clin Obstet Gynecol Date: 2017-12 Impact factor: 2.190

Review 2. [Histopathology and clinical aspects of extrauterine pregnancy].

Authors: L-C Horn; S Opitz; R Handzel; C E Brambs
Journal: Pathologe Date: 2018-09 Impact factor: 1.011

3. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors: A Oaknin; R Guarch; P Barretina; D Hardisson; A González-Martín; X Matías-Guiu; A Pérez-Fidalgo; B Vieites; I Romero; J Palacios
Journal: Clin Transl Oncol Date: 2017-08-16 Impact factor: 3.405

4. Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups.

Authors: Margreet G E M Ausems; Joanne A de Hullu; Vera M Witjes; Jozé C C Braspenning; Nicoline Hoogerbrugge; Yvonne H C M Smolders; Dorien M A Hermkens; Marian J E Mourits; Marjolijn J L Ligtenberg
Journal: Fam Cancer Date: 2022-05-16 Impact factor: 2.375

5. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.

Authors: Konstantin Weber-Lassalle; Corinna Ernst; Alexander Reuss; Kathrin Möllenhoff; Klaus Baumann; Christian Jackisch; Jan Hauke; Dimo Dietrich; Julika Borde; Tjoung-Won Park-Simon; Lars Hanker; Katharina Prieske; Sandra Schmidt; Nana Weber-Lassalle; Esther Pohl-Rescigno; Stefan Kommoss; Frederik Marmé; Florian Heitz; Julia C Stingl; Rita K Schmutzler; Philipp Harter; Eric Hahnen
Journal: J Natl Cancer Inst Date: 2022-04-11 Impact factor: 13.506

6. Germline BRCA variants, lifestyle and ovarian cancer survival.

Authors: Kate Gersekowski; Rachel Delahunty; Kathryn Alsop; Ellen L Goode; Julie M Cunningham; Stacey J Winham; Paul Pharoah; Honglin Song; Susan Jordan; Sian Fereday; Anna DeFazio; Michael Friedlander; Andreas Obermair; Penelope M Webb
Journal: Gynecol Oncol Date: 2022-04-07 Impact factor: 5.304

7. New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.

Authors: I Vergote; V Bours; B Blaumeiser; J-F Baurain
Journal: Facts Views Vis Obgyn Date: 2016-09